Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Cerus Corporation is a medical devices business based in the US. Cerus Corporation shares (CERS) are listed on the NASDAQ and all prices are listed in US Dollars. Cerus Corporation employs 631 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $5.29 |
|---|---|
| 52-week range | $4.35 - $8.06 |
| 50-day moving average | $4.95 |
| 200-day moving average | $5.80 |
| Wall St. target price | $9.40 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.29 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $5.29 from 2022-06-30
| 1 week (2022-06-24) | -4.68% |
|---|---|
| 1 month (2022-06-01) | 9.30% |
| 3 months (2022-03-31) | -3.64% |
| 6 months (2021-12-30) | -23.99% |
| 1 year (2021-07-02) | -5.70% |
|---|---|
| 2 years (2020-07-02) | -21.75% |
| 3 years (2019-07-02) | 1.34% |
| 5 years (2017-06-30) | 110.76% |
| Revenue TTM | $144.9 million |
|---|---|
| Gross profit TTM | $67.4 million |
| Return on assets TTM | -11.96% |
| Return on equity TTM | -56.87% |
| Profit margin | -33.95% |
| Book value | $0.45 |
| Market capitalisation | $935.8 million |
TTM: trailing 12 months
We're not expecting Cerus Corporation to pay a dividend over the next 12 months.
Over the last 12 months, Cerus Corporation's shares have ranged in value from as little as $4.35 up to $8.06. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cerus Corporation's is 1.2123. This would suggest that Cerus Corporation's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California. .
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.